|Videos|May 13, 2020

Contagion Live News Network: Benefits & Pitfalls of an Immunity Passport

A summary of today's top stories.

Hello and thank you for joining Contagion. I’m assistant editor Grant Gallagher, here with a review of our coverage from May 13, 2020.

Although it’s still uncertain just how much immunity is conferred by recovery from coronavirus 2019 (COVID-19), the prospect of certifying an immunity-based "passport," or "license" related to pandemic restrictions has been floated in countries around the globe as a potential reopening measure.

Unlike past immunity certificate programs that have been somewhat limited in scope, like yellow fever vaccination certificate to travel to affected regions, or evidence of being tuberculosis-free to work in healthcare facilities or schools, an immunity certificate program for COVID-19 could have wide-ranging effects according to a pair of essays in the Journal of the American Medical Association that we covered today.

"Conditioned 'privileges' could include a greater range of fundamental civil liberties and opportunities like freedom of association, worship, work, education and travel.", the authors noted. This would potentially put new parts of everyday social life under surveillance, highlighting the need for caution adopting sweeping measures.

We also featured an interview with Dr. Paul Sax, who discusses remdesivir, scientific literature in the age of COVID-19, and the pandemic's long-lasting effects on the future of health care.

And in non-COVID news, a recent study highlighted that Medicaid Doesn't Cover All 13 Recommended Adult Vaccines in Most States. Barriers to recommended vaccine coverage for low-income American adults include disparity in Medicaid programs and low reimbursement amounts.

For more on all of these stories and other infectious disease news, visit contagionlive.com. For Contagion, I’m Grant Gallagher, thanks for watching.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.